Sildenafil Teva
From £3.99
Clinical Evidence and Safety Profile for Sildenafil
BNF Classification and Mechanism of Action
The British National Formulary classifies sildenafil under section 7.4.5 as a phosphodiesterase type-5 inhibitor. Clinical research demonstrates that sildenafil selectively inhibits the PDE5 enzyme, which is responsible for the breakdown of cyclic guanosine monophosphate (cGMP). This mechanism allows for improved blood flow to penile tissues when combined with sexual stimulation, addressing the physiological aspects of erectile dysfunction.
Pivotal Clinical Trial Evidence
The evidence base for sildenafil includes multiple randomised controlled trials involving over 4,000 men with erectile dysfunction of various aetiologies. Clinical studies published in peer-reviewed journals demonstrate efficacy rates of 60-85% across different patient populations. The research shows consistent improvements in erectile function scores, with effects typically observed within 30-60 minutes of administration and lasting approximately 4-6 hours.
Dosing Evidence and BNF Recommendations
Clinical trials established the optimal starting dose of 50mg, as referenced in current BNF guidance. Research supports dose adjustments to 25mg for patients experiencing side effects, or increases to 100mg for those requiring enhanced efficacy. Studies confirm that exceeding one dose per 24-hour period does not improve effectiveness but may increase the risk of adverse effects.
Safety Monitoring and Contraindications
Post-marketing surveillance and clinical studies have identified important safety considerations detailed in the BNF. Research confirms serious contraindications with nitrate medications, which can cause potentially fatal hypotension. Clinical evidence supports cardiovascular screening requirements, particularly for patients with existing heart conditions or those taking multiple medications.
Generic vs Branded Formulations
Bioequivalence studies demonstrate that generic sildenafil contains the same active ingredient as branded Viagra, with equivalent therapeutic effects. Regulatory authorities require generic versions to meet identical quality standards and demonstrate comparable absorption rates. Clinical outcomes research shows no significant differences in effectiveness between branded and generic formulations, allowing patients to choose based on preference and cost considerations.
Real-World Effectiveness Studies
Long-term observational studies complement controlled trial data, showing sustained effectiveness with continued use. Research indicates high patient satisfaction rates, with approximately 80% of men continuing treatment beyond the initial trial period. Clinical audits demonstrate that proper patient selection through thorough medical assessment optimises treatment outcomes and minimises adverse effects.
Current Research and Future Developments
Ongoing clinical research continues to refine understanding of sildenafil's applications and optimal use patterns. Recent studies examine combination approaches and personalised dosing strategies. This evolving evidence base ensures that clinical guidelines, including BNF recommendations, remain current with the latest safety and efficacy data.
